Genitourinary Cancers

Learn more about these products as well as a powered exam table and an app that measures, monitors, and helps improve fertility in men.

In this interview Mark A. Preston, MD, MPH, of Brigham and Women’s hospital sat down with Richard. R. Kerr, Urology Times content channel director, to discuss the association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts. The interview was conducted during the AUA annual meeting in New Orleans.

Other pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.

Other products highlighted in this slideshow include a trial system for incontinence therapy, a compact catheter, a wearable digital technology solution for continence care assessment and management, and laser fiber and sheath system.

A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.

Work-related risks for bladder cancer are on the rise, but the occupations putting workers at risk seem to be evolving, according to a meta-analysis published online in JAMA Oncology (Oct. 8, 2015).

Study findings point to “a concept that has haunted clinical trialists for years,” says one expert.

An immune checkpoint inhibitor provides “a real opportunity to change clinical practice” for patients with metastatic renal cell carcinoma, a study author says.

Researchers have recently made progress in understanding a fundamental signaling cascade, the Programmed Death 1 (PD-1) receptor-ligand pathway,1 which holds long-awaited promise in bladder cancer intervention.

In this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.

A new study reports no statistically significant increase in the risk of bladder cancer among patients treated with the diabetes drug pioglitazone (Actos), despite previous studies suggesting an association.

In this round-up of new urology products and services, learn about an app that helps moviegoers with OAB, a new mesh for sacrocolpopexy, and device/smartphone app that help women with pelvic floor exercises.

Urology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas-an information-packed, condensed summary of the top papers and presentations.

The survival benefit associated with high-dose IL-2 in metastatic renal cell carcinoma may be better than previously believed.

Other products featured include: Radiosurgery collimator allows treatment of broad rang of tumors and Phi prostate cancer test and more.

Products in the pipeline for prostate cancer, bladder cancer, and much more.

Near-infrared fluorescence-guided selective clamping with indocyanine green fluorescent dye in robot-assisted partial nephrectomy appears to be a promising technique to delineate renal tumor anatomy for the bloodless resection of renal masses while minimizing ischemic damage to the kidney.

Remaining on preventive antiplatelet therapy with aspirin significantly increases the risk of bleeding complications in patients undergoing partial nephrectomy, according to research presented at the European Association of Urology annual congress in Madrid, Spain.

Other products featured include a spacer system to protect men undergoing PCa radiotherapy, a pelvic floor exercise app, and more.

Two case studies of stereotactic ablative radiation therapy yielded survival times comparable to those seen with surgical treatment.

Products in the pipeline for prostate cancer, bladder cancer, stress urinary incontinence, chronic prostatitis/chronic pelvic pain syndrome, hypoactive sexual desire disorder.

Two angiogenesis inhibitors that are widely used in metastatic renal cell carcinoma did not improve survival compared with placebo when used as adjuvant treatment, a new study found.

A novel optical imaging technology is showing promise as a potential diagnostic tool for renal cell carcinoma.

New, large-scale studies on active surveillance, IMRT complications, and robotic versus open prostatectomy were among the highlights of this year’s Genitourinary Cancers Symposium.

If further work with irreversible electroporation refines its capacity for discrete tissue ablation deep within the kidney and adjacent to large blood vessels, and especially if larger tumors can be addressed, then this would be a major step forward in the minimally invasive treatment of localized renal cancer.